Real-world outcomes with rituximab vs. conventional therapy in pemphigus vulgaris: a single-center Romanian cohort
In this real-world cohort, rituximab demonstrated superior disease control and relapse prevention compared with conventional therapy. Despite limited follow-up, findings support earlier use of rituximab in PV management to reduce relapse burden and long-term corticosteroid exposure. Broader access to rituximab and improved diagnostic resources could meaningfully improve outcomes in resource-limited settings.
Authors
- Catalina Branisteanu
- Daciana Elena Branisteanu (ORCID: https://orcid.org/0000-0002-0368-8694)
- Torello Lotti (ORCID: https://orcid.org/0000-0003-0840-1936)
- Mihaela Paula Toader (ORCID: https://orcid.org/0000-0002-9838-836X)
- Daniel Brănișteanu (ORCID: https://orcid.org/0009-0009-5147-9596)
- George Brănișteanu
- Catalina Munteanu (ORCID: https://orcid.org/0000-0003-1616-9639)
- Ștefan Vasile Toader
- Roxana Paraschiva Ciobanu
- Alin Gabriel Colac
- Antonia Elena Huțanu
- Cristina Colac Boțoc
Institutions
- Clinical Emergency Hospital Bucharest (RO)
- Marconi University (IT)
- South Eastern Railway (IN)
- Grigore T. Popa University of Medicine and Pharmacy (RO)
- Institutul de Urgenţă pentru Boli Cardiovasculare "Prof.Dr. C.C. Iliescu" (RO)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-12
- DOI
- https://doi.org/10.3389/fmed.2025.1691897
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00